P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE

The risk of developing severe symptoms caused by SARS-CoV2 infection in patients (pts) with cutaneous mastocytosis (CM), or indolent systemic mastocytosis (ISM) is like that of healthy people. Unfortunately, the risk may increase in pts with aggressive systemic mastocytosis (ASM), or mastocytosis associated to a hematologic neoplasm (SM-AHN). SARS-CoV2 vaccination reduces the risk of a potentially fatal infection. Considering the increased risk of allergic reactions, it is crucial for these pts to be safely vaccinated. The incidence of vaccine-related anaphylaxis has been reported to be 5 times higher for mRNA vaccines than others. The Italian Ministry of Health (MH) suggests mRNA vaccines for frail individuals. In pts with mastocytosis, it recommended prophylaxis with antihistamines from the day prior to the vaccination to 5 days after, and an observation of 60 min after the vaccination. The administration of the vaccine in a hospital setting was recommended in those with a history of anaphylaxis episodes. In our hospital a vaccination campaign for frail pts in 2 phases was organized.